Researchers offer further insight into the mechanism of acute exacerbations in idiopathic pulmonary fibrosis (IPF) and a potential antibody treatment to inhibit this process and published their results in Nature Communications. They developed and tested the amelioration of lung fibrosis using an anticorisin monoclonal antibody (mAtb).

“We recently identified a proapoptotic peptide termed corisin in the lung microbiome that may explain the pathogenic role of microbial alteration in pulmonary fibrosis,” the authors wrote. “Intrapulmonary administration of corisin or corisin-harboring bacterium causes apoptosis of alveolar epithelial cells and [acute exacerbations] in mice with established pulmonary fibrosis.”

The research team first confirmed the impact of corisin, a proapoptotic peptide in high concentrations in serum from patients with IPF with acute exacerbations and derived from 3 Staphylococcus haemolyticus strains, on the pathogenesis of acute exacerbations and acute lung injury.


Continue Reading

Read more about IPF prognosis

The results obtained demonstrate the causative role of corisin in acute exacerbations as well as the benefits of the newly developed anticorisin mAtb on lung fibrosis.

The authors are hopeful that these outcomes signal the potential of corisin in serum from patients with IPF to become a useful biomarker for pulmonary fibrosis, not only in IPF but in other lung diseases with underlying fibrosis, as has been detected in patients who recovered from severe acute respiratory syndrome. Furthermore, the anticorisin mAtb offers a possible novel treatment approach for these patients.

They then investigated the effect of a neutralizing antibody against corisin on acute exacerbations in pulmonary fibrosis and lipopolysaccharide-induced acute lung injury. They treated mice with induced acute lung injury with neutralizing mAtb or control immunoglobulin G (IgG), and the mAtb-treated mice demonstrated significantly reduced Ashcroft and CT fibrosis scores compared with the mice treated with the control IgG.

Reference

D’Alessandro-Gabazza CN, Yasuma T, Kobayashi T, et al. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. Nat Commun. Published online March 23, 2022. doi:10.1038/s41467-022-29064-3